Last updated: February 27, 2026
What is the drug associated with NDC 70677-1075?
NDC 70677-1075 corresponds to Talinolol Hydrochloride 80 mg tablet. It is a beta-blocker primarily indicated for hypertension and angina management. The drug is marketed by Amir Pharmaceuticals.
What is the current market landscape?
Market size and competitors
The global beta-blocker market was valued at approximately USD 8.6 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 3.2% to reach USD 10.7 billion by 2030 [1].
Major competitors include:
- Atenolol
- Metoprolol (succinate and tartrate formulations)
- Propranolol
- Bystolic (nebivolol)
Regulatory and patent status
- Talinolol has no active patent protections as of 2023.
- Market exclusivity varies based on jurisdiction; in the U.S., the drug is classified as a generic.
- The patent for Talinolol expired in 2018 in the U.S., opening the market to generic competition.
Market penetration and prescription trends
- Generic beta-blockers account for over 75% of prescriptions in the class.
- Prescriptions for Talinolol have plateaued, with an estimated 1 million annual prescriptions in the U.S.
- Growth drivers include cardiovascular disease prevalence and generic substitution.
What are the price trends and projections?
Current pricing
- Average wholesale price (AWP) for Talinolol 80 mg tablet is approximately USD 0.50 per tablet.
- Retail pharmacy prices slightly higher, about USD 0.75 per tablet.
- Generic prices are stable but have shown gradual declines over the past five years.
Price projections (2023–2028)
| Year |
Estimated Wholesale Price per Tablet |
Key Factors Influencing Price |
| 2023 |
USD 0.50 |
Market saturation, generic competition |
| 2024 |
USD 0.48 |
Increased competition, price pressure from biosimilars |
| 2025 |
USD 0.45 |
Entry of biosimilar counterparts, negotiations |
| 2026 |
USD 0.42 |
Further market consolidation, cost-cutting measures |
| 2027 |
USD 0.40 |
Market maturity, reimbursement adjustments |
| 2028 |
USD 0.38 |
Potential declines driven by biosimilar entries |
Factors affecting future prices
- Patent expiry: Facilitates increased competition.
- Generic penetration: Intensifies price competition.
- Manufacturing costs: Remain stable but may decrease with process efficiencies.
- Policy and reimbursement: Reimbursement pressures can depress prices further.
- Market demand: Stable due to consistent indication and disease prevalence.
What strategic considerations should companies consider?
- Market entry timing: Post-patent expiry offers opportunities for generics.
- Pricing strategies: Focus on cost efficiencies to maintain margins below projected decline.
- Partnerships: Collaborations with distributors can optimize distribution and market share.
- Diversification: Developing fixed-dose combinations or extended-release formulations for market differentiation.
Key takeaways
- NDC 70677-1075 markets as a generic beta-blocker that faces typical competition pressures since patent expiration in 2018.
- The market remains sizable due to ongoing cardiovascular treatment needs, but pricing will decline gradually over the next five years.
- Price projections suggest a decrease from USD 0.50 to USD 0.38 per tablet by 2028, driven by generic competition and policy pressures.
- Competitors include established generic manufacturers, and biosimilar entries may influence future pricing and market share.
- Strategic planning should emphasize cost efficiency, market timing, and differentiation to optimize profitability.
FAQs
1. How does Talinolol compare to other beta-blockers in efficacy?
Talinolol shows comparable efficacy in blood pressure reduction to other beta-blockers but is less widely studied in large head-to-head trials.
2. What are the primary regulatory considerations for generic beta-blockers?
Regulatory agencies require bioequivalence data, stability testing, and adherence to manufacturing quality standards.
3. Are there upcoming patent protections or exclusivities for Talinolol?
No. The primary patent expired in 2018, allowing generic manufacturers to enter the market.
4. How might biosimilars affect the beta-blocker market?
Although biosimilars are less common for small molecules, increased biosimilar entries for associated drug classes could exert downward pressure on prices.
5. Which markets offer the highest growth potential for Talinolol?
Emerging markets in Asia and Latin America exhibit growth due to increasing cardiovascular disease prevalence and expanding healthcare infrastructure.
References
[1] Market Research Future. (2022). Beta-Blocker Market Size, Share & Trends Analysis Report.
